Navigation Links
New agent may enhance effectiveness of radiotherapy
Date:5/13/2014

Scientists from The University of Manchester part of the Manchester Cancer Research Centre - have demonstrated the potential of a drug to improve the effectiveness of radiotherapy in stopping tumour growth.

There is increasing interest in using the body's own immune system to attack tumour cells a strategy that can be very effective without the side effects associated with conventional chemotherapy.

Skin cancers have been successfully treated using a topical cream, imiquimod, which recruits immune cells through a molecule known as toll-like receptor 7 (TLR7), a protein that recognises foreign and potentially harmful material.

Previously, researchers in Manchester have shown that they can also stimulate the immune system into generating an immune response against non-skin cancers by injecting an agent similar to TLR7 into the blood.

In collaboration with AstraZeneca and Dainippon Sumitomo Pharma, the Manchester group have looked at another molecule that activates TLR7, known as DSR-6434. Using mouse models of two different types of cancer, they investigated DSR-6434 on its own and in combination with radiotherapy and measured the effect on the primary tumour and the number of secondary tumours in the lungs.

Professor Ian Stratford, from Manchester Pharmacy School who, with Professor Tim Illidge, led the research published in the International Journal of Cancer, said: "We have already seen a strong immune system response from other immunotherapy agents in combination with radiation this new agent appears to be even more potent."

His team showed that administering DSR-6434 together with radiotherapy led to tumour shrinkage and increased long-term survival. They found that the combination treatment also reduced the occurrence of secondary lung tumours.

"It looks like there's good reason to use radiotherapy alongside immunotherapy agents in the treatment of solid tumours. These results strongly suggest that this sort of combination therapy should be evaluated in clinical trials with cancer patients," added Professor Stratford.


'/>"/>

Contact: Ali Barbuti
alison.barbuti@manchester.ac.uk
44-016-127-58383
University of Manchester
Source:Eurekalert

Related medicine news :

1. Pig stomach mucins are effective as anti-viral agents for consumer products
2. Imaging agents predict breast cancer response to endocrine therapy
3. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
4. New substances 15,000 times more effective in destroying chemical warfare agents
5. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
6. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
7. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
8. Travel Services (MyTSOnline) in Valencia Teams Up With Vendors to Become the Number One Travel Agent in the Santa Clarita Valley
9. Rilpivirine for HIV: Added benefit for single agent proven
10. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
11. Investigational agent targets gene signaling pathways to improve response for patients with CLL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 04, 2016 , ... Are You Concerned About Mold In Your Home ... Indoor Air Quality Companies in VA, MD and DC, recently completed its application for ... new mold law in the district of Columbia is a good thing stated John ...
(Date:12/2/2016)... ... December 02, 2016 , ... Halfway through its partnership with ... preventative dental services to more than 15,900 children 5 years old and younger and ... $38 million over a span of five years to Western University of Health Sciences, ...
(Date:12/2/2016)... ... , ... Two years ago, Arizona State University students produced ... 1 million viewers and won numerous honors, including the region’s top Emmy and ... Cronkite School of Journalism and Mass Communication are following up their award-winning investigation ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... , ... Advanced Inc., a leading provider of travel therapy and travel nursing ... as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as ... operational leadership experience to Advanced Inc. He began his career in finance at Ernst ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Va. , Dec. 2, 2016  The ... by the Academy of Managed Care Pharmacy (AMCP), ... organizations can better address the opioid addiction crisis, ... Assisted Therapies (MAT). ATAG,s newly released ... Improving Access to Naloxone," addresses many issues around ...
(Date:12/2/2016)... Boston Scientific Corporation (NYSE: BSX ... manufacturing assets and capabilities of the Neovasc, Inc., (NASDAQ: ... business, as well as a 15% equity stake in ... The Neovasc advanced biological tissue business makes elements used ... Valve System. * Upon completion of the transaction, ...
(Date:12/2/2016)... YORK , December 2, 2016 ... 5,251.11, down 1.36%; the Dow Jones Industrial Average edged 0.36% ... at 2,191.08, down 0.35%. Losses were broad based as six ... Stock-Callers.com has initiated research reports on the following Services equities: ... (NASDAQ: QGEN ), INC Research Holdings Inc. (NASDAQ: ...
Breaking Medicine Technology: